Jefferies Leaves CVS Caremark $39 PT, Buy Rating Unchanged (CVS)

Jefferies left its CVS Caremark CVS Buy rating and $39 price target unchanged in a research report published today. In the report, Jefferies states, "CVS/Caremark's valuation remains quite attractive as does its significant cash flow generation. The PBM, however, is still struggling to find its footing which is putting significant demands on the retail operations to perform. Let's hope it does not buckle under the pressure." Shares of CVS Caremark were at $33.28 in Thursday after market trading, down 0.12% from Thursday's market close.